$44.42
-1.09 (-2.40%)
OMCL News2 articles
Omnicell Shares Jump 17.5% on Q1 Beat, Raised 2026 Guidance
Omnicell shares jumped 17.5% after Q1 results topped estimates and the company raised its 2026 profit outlook, citing strong demand for its Titan XT system.
Hims & Hers Soars on FDA Catalyst as Omnicell Underperforms
Hims & Hers Health shares surged nearly 9% Monday, extending a strong weekly gain ahead of its May earnings report and a key FDA meeting on peptides. Omnicell reported mixed Q4 results with a net loss.